Next-Generation Antibody–Drug Conjugates: Optimizing Payloads, Linkers, and Tumor Selectivity

Abstract

Antibody–drug conjugates (ADCs) represent a rapidly evolving class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs. Recent advances in ADC design have focused on optimizing payloads, linkers, and tumor selectivity to maximize clinical efficacy while minimizing off-target toxicity. This review provides a detailed analysis of the current landscape and future direction of next-generation ADCs, integrating evidence from clinical trials, mechanistic studies, and guideline recommendations relevant to oncologists and healthcare professionals. Emphasis is placed on the interplay between ADC components, their impact on therapeutic index, and their role in overcoming resistance in solid and hematologic malignancies.

Introduction

Antibody–drug conjugates (ADCs) have emerged as a pivotal innovation in oncology, leveraging the tumor-targeting capacity of monoclonal antibodies to deliver highly cytotoxic agents directly to malignant cells. Over the past decade, the clinical landscape has witnessed a surge in ADC approvals across various tumor types, including breast, hematologic, and urothelial cancers. The complexity of ADCs, encompassing the antibody, linker, and cytotoxic payload, necessitates continual refinement to balance efficacy and safety. This review explores the scientific rationale, clinical data, and mechanistic underpinnings guiding the development of next-generation ADCs, aiming to inform clinicians regarding current best practices and future perspectives in ADC-based therapy.

Epidemiology / Disease Burden

Cancer remains a major global health burden, with solid tumors and hematologic malignancies accounting for millions of deaths annually. Despite advances in surgery, chemotherapy, radiation, and immunotherapy, a significant proportion of patients with advanced or refractory disease experience limited survival benefits. The unmet need for more selective and effective therapies underpins the rapid development of ADCs. Epidemiological data indicate that ADCs are increasingly incorporated into treatment algorithms for diseases such as HER2-positive breast cancer, relapsed/refractory lymphoma, and urothelial carcinoma, addressing substantial patient populations with otherwise poor prognoses.

Pathophysiology

The therapeutic principle of ADCs is predicated on the differential expression of cell surface antigens on tumors versus normal tissues. Monoclonal antibodies target these antigens, serving as vehicles for delivering cytotoxic payloads directly into malignant cells. Upon binding, the ADC–antigen complex is internalized, and the linker is degraded either enzymatically or by the tumor microenvironment releasing the active drug within the cell. This targeted approach minimizes systemic exposure and associated toxicities. However, antigen heterogeneity, antigen shedding, and drug efflux mechanisms can compromise ADC efficacy, underscoring the importance of continuous molecular refinement.

Risk Factors

Optimal ADC efficacy depends on several tumor- and patient-specific factors. High and homogeneous antigen expression, efficient internalization, and limited antigen presence on normal tissue are critical for therapeutic selectivity. Risk factors for suboptimal response include antigen loss or downregulation, upregulation of multidrug resistance proteins, and compromised endocytosis. Patient-related factors, such as prior therapies, comorbidities, and immune status, may also influence the pharmacodynamics and toxicity profile of ADCs. Identifying and stratifying these risk factors is essential for patient selection and therapeutic optimization.

Clinical Features

Clinically, ADCs are indicated for patients with tumors expressing the relevant target antigen, often in the relapsed or refractory setting. The clinical syndrome after ADC administration may include typical chemotherapy-related adverse events as well as unique toxicities such as infusion reactions, hepatotoxicity, ocular disorders, and peripheral neuropathy, depending on the payload and target. Recognizing and managing these features is crucial for maximizing benefit and minimizing harm. Notably, next-generation ADCs seek to reduce off-target effects through improved tumor selectivity and linker stability.

Diagnosis

The selection of patients for ADC therapy hinges on accurate and reproducible assessment of antigen expression, typically via immunohistochemistry or in situ hybridization on tumor biopsies. Advanced molecular diagnostics, including next-generation sequencing and digital pathology, are increasingly employed to characterize antigen heterogeneity and predict response. Ongoing research aims to refine diagnostic criteria to better match patients to specific ADCs and anticipate resistance mechanisms.

Treatment & Management

ADCs are administered intravenously, often in combination with other systemic therapies or as monotherapy in specific indications. Dosage and scheduling are tailored to the pharmacokinetics of the antibody, linker, and payload, as well as patient-specific factors. Management of ADC-related toxicities requires multidisciplinary expertise, prompt recognition, and evidence-based interventions, including dose modification, supportive care, and in some instances, discontinuation of therapy. Clinical guidelines recommend regular monitoring for hematologic, hepatic, and neurologic side effects, with proactive measures to mitigate risk.

Recent Advances / Emerging Therapies

Next-generation ADCs incorporate novel strategies to enhance therapeutic index. Innovations include site-specific conjugation techniques for more uniform drug-to-antibody ratios, use of cleavable and non-cleavable linkers optimized for stability and controlled release, and payloads with unique mechanisms such as DNA alkylation, tubulin inhibition, or immunomodulation. Bispecific antibodies, dual payloads, and combination regimens with checkpoint inhibitors represent active areas of investigation. Recent clinical trials, such as those evaluating trastuzumab deruxtecan and sacituzumab govitecan, demonstrate significant improvements in progression-free and overall survival in multiple tumor types, underscoring the potential of these sophisticated ADC platforms.

Guideline Recommendations

Major oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO), now incorporate ADCs as standard-of-care options in several cancer subtypes. Recommendations emphasize patient selection based on antigen testing, vigilant monitoring for toxicities, and integration with other modalities as appropriate. Shared decision-making and individualized care plans are advocated, particularly as real-world data mature and novel ADCs become available outside clinical trials.

Conclusion

Next-generation antibody–drug conjugates represent a paradigm shift in targeted cancer therapy, offering the promise of greater efficacy and reduced toxicity through optimized payloads, linker chemistry, and tumor selectivity. Ongoing research and clinical experience continue to refine their role in oncology, with future directions likely to expand indications, improve patient outcomes, and address resistance mechanisms. Interdisciplinary collaboration, rigorous diagnostic approaches, and adherence to evolving guidelines will be essential to realize the full potential of ADCs in cancer care.